Compare Incyte Corporation (INCY) vs Millicom International Cellular S.A. Common Stock (TIGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Millicom International Cellular S.A. Common Stock — how do they compare? Incyte Corporation trades at $111.75 (market cap $22.63B), while Millicom International Cellular S.A. Common Stock trades at $80.51 (market cap $13.49B). The key difference: Incyte Corporation is the larger of the two by market cap, and Millicom International Cellular S.A. Common Stock pays a 3.73% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Millicom International Cellular S.A. Common Stock for 0 Days on average.
| INCY | TIGO | |
|---|---|---|
Market Cap | $22.63B | $13.49B |
Volume | 1,869,988 | 1,314,537 |
Sector | Health | Media |
52-Week High | $129.93 | $104.31 |
52-Week Low | $86.17 | $45.81 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $18.13B | $24.53B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $108.62, down 2.46% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 13.84, robust profitability margins, and a significant earnings beat in Q2 2026. Recent news highlights FDA approval for Atebrioz and a strategic push for post-JAKAFI growth targeting $4B in sales. Operating cash flow surged to $1.41B in 2025, supporting financial health.
The outlook is mixed: analyst consensus is bullish with a $133.14 price target, but near-term technical pressure and Q3 2026's expected EPS loss pose risks. Long-term growth depends on pipeline execution and diversification beyond JAKAFI, with competitive and regulatory challenges as key investor considerations.
TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.
The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Millicom International Cellular S.A. Common Stock
Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.
Read more on TIGO →
